{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:59:45Z","timestamp":1790805585224,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/eye.2015.251","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T05:31:48Z","timestamp":1452231108000},"page":"202-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Photodynamic therapy: current role in the treatment of chorioretinal conditions"],"prefix":"10.1038","volume":"30","author":[{"given":"D K","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"BFeye2015251_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/jnci\/90.12.889","volume":"90","author":"TJ Dougherty","year":"1998","unstructured":"Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889\u2013905.","journal-title":"J Natl Cancer Inst"},{"key":"BFeye2015251_CR2","first-page":"505","volume":"23","author":"MB Vrouenraets","year":"2003","unstructured":"Vrouenraets MB, Visser GW, Snow GB, van Dongen GA . Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res 2003; 23: 505\u2013522.","journal-title":"Anticancer Res"},{"key":"BFeye2015251_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(04)01529-3","volume":"5","author":"SB Brown","year":"2004","unstructured":"Brown SB, Brown EA, Walker I . The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5: 497\u2013508.","journal-title":"Lancet Oncol"},{"key":"BFeye2015251_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/00055735-200006000-00002","volume":"11","author":"CD Regillo","year":"2000","unstructured":"Regillo CD . Update on photodynamic therapy. Curr Opin Ophthalmol 2000; 11: 166\u2013170.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2015251_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archopht.117.9.1161","volume":"117","author":"JW Miller","year":"1999","unstructured":"Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1161\u20131173.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015251_CR6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1001\/archopht.117.9.1177","volume":"117","author":"U Schmidt-Erfurth","year":"1999","unstructured":"Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1177\u20131187.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015251_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/archopht.1995.01100060136048","volume":"113","author":"JW Miller","year":"1995","unstructured":"Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte TJ et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995; 113: 810\u2013818.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015251_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0039-6257(00)00158-2","volume":"45","author":"U Schmidt-Erfurth","year":"2000","unstructured":"Schmidt-Erfurth U, Hasan T . Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195\u2013214.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2015251_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0161-6420(96)30675-1","volume":"103","author":"M Kramer","year":"1996","unstructured":"Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996; 103: 427\u2013438.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR10","first-page":"198","volume":"119","author":"Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group","year":"2001","unstructured":"Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol 2001; 119: 198\u2013207.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015251_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541\u2013560.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/archopht.123.4.448","volume":"123","author":"Visudyne in Minimally Classic Choroidal Neovascularization Study Group","year":"2005","unstructured":"Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123: 448\u2013457.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015251_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/IAE.0b013e318156777f","volume":"28","author":"WM Chan","year":"2008","unstructured":"Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS . Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008; 28: 85\u201393.","journal-title":"Retina"},{"key":"BFeye2015251_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/IAE.0b013e3181e378f2","volume":"31","author":"JY Shin","year":"2011","unstructured":"Shin JY, Woo SJ, Yu HG, Park KH . Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011; 31: 119\u2013126.","journal-title":"Retina"},{"key":"BFeye2015251_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ajo.2010.12.007","volume":"151","author":"M Reibaldi","year":"2011","unstructured":"Reibaldi M, Boscia F, Avitabile T, Uva MG, Russo A, Zagari M et al. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2011; 151: 953\u2013960.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et alMARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419\u20131431.","journal-title":"N Engl J Med"},{"key":"BFeye2015251_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432\u20131444.","journal-title":"N Engl J Med"},{"key":"BFeye2015251_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T . ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57\u201365.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR19","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.ophtha.2012.02.002","volume":"119","author":"M Larsen","year":"2012","unstructured":"Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E et alMONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012; 119: 992\u20131000.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ophtha.2012.02.003","volume":"119","author":"PK Kaiser","year":"2012","unstructured":"Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A . DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119: 1001\u20131010.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR21","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.ophtha.2013.03.016","volume":"120","author":"K Tozer","year":"2013","unstructured":"Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 2013; 120: 2029\u20132034.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/archopht.118.3.327","volume":"118","author":"M Sickenberg","year":"2000","unstructured":"Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000; 118: 327\u2013336.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015251_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial. VIP Report No 1. Ophthalmology 2001; 108: 841\u2013852.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","volume":"110","author":"KJ Blinder","year":"2003","unstructured":"Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial. VIP Report No 3. Ophthalmology 2003; 110: 667\u2013673.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/bjo.2007.132795","volume":"92","author":"JM Ruiz-Moreno","year":"2008","unstructured":"Ruiz-Moreno JM, Amat P, Montero JA, Lugo F . Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008; 92: 792\u2013794.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","volume":"148","author":"K Hayashi","year":"2009","unstructured":"Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009; 148: 396\u2013408.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/bjo.2009.166025","volume":"94","author":"T Baba","year":"2010","unstructured":"Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S . Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010; 94: 864\u2013870.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T et alRADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014; 121: 682\u2013692.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","volume":"99","author":"TY Wong","year":"2015","unstructured":"Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, Lai TY, Yu HG et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol 2015; 99: 289\u2013296.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/00006982-200202000-00003","volume":"22","author":"Verteporfin Roundtable 2000 and 2001 Participants","year":"2002","unstructured":"Verteporfin Roundtable 2000 and 2001 Participants. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22: 6\u201318.","journal-title":"Retina"},{"key":"BFeye2015251_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ophtha.2010.04.016","volume":"118","author":"JS Heier","year":"2011","unstructured":"Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S et al. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 2011; 118: 111\u2013118.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ajo.2012.10.010","volume":"155","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ . Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. Am J Ophthalmol 2013; 155: 713\u2013719.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR33","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0161-6420(02)01454-9","volume":"109","author":"UM Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth UM, Michels S, Kusserow C, Jurklies B, Augustin AJ . Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology 2002; 109: 2284\u20132294.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/bjo.87.1.84","volume":"87","author":"B Jurklies","year":"2003","unstructured":"Jurklies B, Anastassiou G, Ortmans S, Sch\u00fcler A, Schilling H, Schmidt-Erfurth U et al. Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol 2003; 87: 84\u201389.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0161-6420(02)01968-1","volume":"110","author":"G Porrini","year":"2003","unstructured":"Porrini G, Giovannini A, Amato G, Ioni A, Pantanetti M . Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology 2003; 110: 674\u2013680.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR36","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/bjo.2004.044396","volume":"88","author":"AD Singh","year":"2004","unstructured":"Singh AD, Kaiser PK, Sears JE, Gupta M, Rundle PA, Rennie IG . Photodynamic therapy of circumscribed choroidal haemangioma. Br J Ophthalmol 2004; 88: 1414\u20131418.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2008.08.029","volume":"116","author":"A Boixadera","year":"2009","unstructured":"Boixadera A, Garc\u00eda-Arum\u00ed J, Mart\u00ednez-Castillo V, Encinas JL, Elizalde J, Blanco-Mateos G et al. Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology 2009; 116: 100\u2013105.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR38","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.12.033","volume":"117","author":"MA Blasi","year":"2010","unstructured":"Blasi MA, Tiberti AC, Scupola A, Balestrazzi A, Colangelo E, Valente P et al. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes. Ophthalmology 2010; 117: 1630\u20131637.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR39","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/archopht.122.10.1471","volume":"122","author":"E Frau","year":"2004","unstructured":"Frau E, Rumen F, Noel G, Delacroix S, Habrand JL, Offret H . Low-dose proton beam therapy for circumscribed choroidal hemangiomas. Arch Ophthalmol 2004; 122: 1471\u20131475.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015251_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.survophthal.2010.08.002","volume":"56","author":"MS Tsipursky","year":"2011","unstructured":"Tsipursky MS, Golchet PR, Jampol LM . Photodynamic therapy of choroidal hemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. Surv Ophthalmol 2011; 56: 68\u201385.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2015251_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ICU.0b013e3283459826","volume":"22","author":"A Ross","year":"2011","unstructured":"Ross A, Ross AH, Mohamed Q . Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011; 22: 166\u2013173.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2015251_CR42","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1177\/112067210801800613","volume":"18","author":"P Lanzetta","year":"2008","unstructured":"Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F . Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol 2008; 18: 934\u2013940.","journal-title":"Eur J Ophthalmol"},{"key":"BFeye2015251_CR43","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ophtha.2010.01.023","volume":"117","author":"I Maruko","year":"2010","unstructured":"Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF . Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010; 117: 1792\u20131799.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR44","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1111\/aos.12482","volume":"92","author":"J Ma","year":"2014","unstructured":"Ma J, Meng N, Xu X, Zhou F, Qu Y . System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 2014; 92: e594\u2013e601.","journal-title":"Acta Ophthalmol"},{"key":"BFeye2015251_CR45","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1136\/bjo.87.12.1453","volume":"87","author":"WM Chan","year":"2003","unstructured":"Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK . Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453\u20131458.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR46","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","volume":"23","author":"LA Yannuzzi","year":"2003","unstructured":"Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288\u2013298.","journal-title":"Retina"},{"key":"BFeye2015251_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/IAE.0b013e3182670fbe","volume":"33","author":"RM Silva","year":"2013","unstructured":"Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Greg\u00f3rio T, Cachulo ML et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina 2013; 33: 309\u2013315.","journal-title":"Retina"},{"key":"BFeye2015251_CR48","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","volume":"115","author":"WM Chan","year":"2008","unstructured":"Chan WM, Lai TY, Lai RY, Liu DT, Lam DS . Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008; 115: 1756\u20131765.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR49","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/IAE.0b013e3181f049d3","volume":"31","author":"K Fujita","year":"2011","unstructured":"Fujita K, Yuzawa M, Mori R . Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina 2011; 31: 772\u2013778.","journal-title":"Retina"},{"key":"BFeye2015251_CR50","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/eye.2013.24","volume":"27","author":"SH Karakus","year":"2013","unstructured":"Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A . Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye 2013; 27: 612\u2013620.","journal-title":"Eye"},{"key":"BFeye2015251_CR51","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/bjophthalmol-2014-305353","volume":"99","author":"CC Tseng","year":"2015","unstructured":"Tseng CC, Chen SN . Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 2015; 99: 1070\u20131077.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR52","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ophtha.2014.09.034","volume":"122","author":"K Fujita","year":"2015","unstructured":"Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K et al. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2015; 122: 555\u2013561.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ajo.2009.08.026","volume":"149","author":"M Reibaldi","year":"2010","unstructured":"Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307\u2013315.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/IAE.0b013e318280769c","volume":"33","author":"E Smretschnig","year":"2013","unstructured":"Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S . Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina 2013; 33: 316\u2013323.","journal-title":"Retina"},{"key":"BFeye2015251_CR55","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajo.2014.01.022","volume":"157","author":"M Nicolo","year":"2014","unstructured":"Nicolo M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2014; 157: 1033\u20131037.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR56","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2147\/OPTH.S58617","volume":"8","author":"Z Alkin","year":"2014","unstructured":"Alkin Z, Perente I, Ozkaya A, Alp D, Agca A, Aygit ED et al. Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Clin Ophthalmol 2014; 8: 685\u2013690.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2015251_CR57","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ophtha.2013.11.040","volume":"121","author":"JI Lim","year":"2014","unstructured":"Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF . Macula Society CSC Collaborative Study Group. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2014; 121: 1073\u20131078.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR58","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/eye.2014.134","volume":"28","author":"OC Erikitola","year":"2014","unstructured":"Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S . Photodynamic therapy for central serous chorioretinopathy. Eye 2014; 28: 944\u2013957.","journal-title":"Eye"},{"key":"BFeye2015251_CR59","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/ICU.0b013e3282fb7c33","volume":"19","author":"F Gomi","year":"2008","unstructured":"Gomi F, Tano Y . Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol 2008; 19: 208\u2013212.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2015251_CR60","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","volume":"33","author":"AH Koh","year":"2013","unstructured":"Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T et al. Expert PCV Panel. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013; 33: 686\u2013716.","journal-title":"Retina"},{"key":"BFeye2015251_CR61","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","volume":"133","author":"M Uyama","year":"2002","unstructured":"Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002; 133: 639\u2013648.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0021-5155(03)00042-X","volume":"47","author":"M Yuzawa","year":"2003","unstructured":"Yuzawa M, Mori R, Haruyama M . A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2003; 47: 379\u2013384.","journal-title":"Jpn J Ophthalmol"},{"key":"BFeye2015251_CR63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/sj.eye.6702955","volume":"23","author":"MW Lee","year":"2009","unstructured":"Lee MW, Yeo I, Wong D, Ang CL . Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye 2009; 23: 145\u2013148.","journal-title":"Eye"},{"key":"BFeye2015251_CR64","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","volume":"111","author":"WM Chan","year":"2004","unstructured":"Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004; 111: 1576\u20131584.","journal-title":"Ophthalmology"},{"key":"BFeye2015251_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2007.03.014","volume":"144","author":"A Otani","year":"2007","unstructured":"Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007; 144: 7\u201314.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR66","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/IAE.0b013e31804b3f70","volume":"27","author":"CM Eandi","year":"2007","unstructured":"Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA . Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 2007; 27: 825\u2013831.","journal-title":"Retina"},{"key":"BFeye2015251_CR67","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","volume":"27","author":"Y Hirami","year":"2007","unstructured":"Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007; 27: 335\u2013341.","journal-title":"Retina"},{"key":"BFeye2015251_CR68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/bjo.2008.150029","volume":"94","author":"GT Kokame","year":"2010","unstructured":"Kokame GT, Yeung L, Lai JC . Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010; 94: 297\u2013301.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ajo.2010.02.008","volume":"150","author":"F Gomi","year":"2010","unstructured":"Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M . Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010; 150: 48\u201354.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2015251_CR70","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453\u20131464.","journal-title":"Retina"},{"key":"BFeye2015251_CR71","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1097\/IAE.0000000000000206","volume":"34","author":"SJ Davis","year":"2014","unstructured":"Davis SJ, Lauer AK, Flaxel CJ . Polypoidal choroidal vasculopathy in white patients. Retina 2014; 34: 2185\u20132191.","journal-title":"Retina"},{"key":"BFeye2015251_CR72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/eye.2011.24","volume":"25","author":"G Jutley","year":"2011","unstructured":"Jutley G, Jutley G, Tah V, Lindfield D, Menon G . Treating peripapillary choroidal neovascular membranes: a review of the evidence. Eye 2011; 25: 675\u2013681.","journal-title":"Eye"},{"key":"BFeye2015251_CR73","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00006982-200501000-00004","volume":"25","author":"BJ Rosenblatt","year":"2005","unstructured":"Rosenblatt BJ, Shah GK, Blinder K . Photodynamic therapy with verteporfin for peripapillary choroidal neovascularization. Retina 2005; 25: 33\u201337.","journal-title":"Retina"},{"key":"BFeye2015251_CR74","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/IAE.0b013e31815e9351","volume":"28","author":"PS Bernstein","year":"2008","unstructured":"Bernstein PS, Horn RS . Verteporfin photodynamic therapy involving the optic nerve for peripapillary choroidal neovascularization. Retina 2008; 28: 81\u201384.","journal-title":"Retina"},{"key":"BFeye2015251_CR75","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/bjo.2008.144196","volume":"92","author":"MS Figueroa","year":"2008","unstructured":"Figueroa MS, Noval S, Contreras I . Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab. Br J Ophthalmol 2008; 92: 1244\u20131247.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2015251_CR76","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/112067210901900128","volume":"19","author":"AE Hoeh","year":"2009","unstructured":"Hoeh AE, Schaal KB, Ach T, Dithmar S . Treatment of peripapillary choroidal neovascularization with intravitreal bevacizumab. Eur J Ophthalmol 2009; 19: 163\u2013165.","journal-title":"Eur J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2015251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2015251","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2015251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:26:18Z","timestamp":1684416378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2015251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFeye2015251"],"URL":"https:\/\/doi.org\/10.1038\/eye.2015.251","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,8]]},"assertion":[{"value":"27 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}